BeiGene, Ltd. BGNE
184.71 0.00 (+0.00%)
At closeDec 31, 2024, 4:00 PM EST
183.91 Day range 187.42
52-week range unavailable
- YTD
- +4.67%
- 1 year
- +4.67%
- Market cap
- 20.21B
- YTD return
- +4.67%
- 1-year return
- +4.67%
- Volume
- 329.40K
- Open
- 184.00
- Previous close
- 184.71
- Day's range
- 183.91 – 187.42
3M -49.64 (-21.25%)
Financials — quick view
BGNE Revenue — quarterly 1.00B
BGNE Net income — quarterly -121.35M
BGNE EPS — quarterly -0.09
News
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb 
President Trump demands drugmakers slash prices within 60 days 
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer 
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors 
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation Innovation 
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference 
Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + 
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit 
BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript 
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
Your note
Sign in to keep a note on BGNE — it syncs with the Stock Master app.